UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.